Founder/CEO & Chairperson
From the Founder:
“After losing both of my parents to cancer, I became very interested in understanding my cancer risk profile, which led me to learn more about genetic testing. I tried to take the test that was available at the time and had a horrible experience – the test was too expensive, took too long to get results, and worse of all, once I got my results, my 60 year old family doctor did not know what to do with them.
I started Artemis DNA to fix those shortcomings.
I wanted to introduce the concept of customer service to the diagnostic space, to make diagnostic testing accessible and their results meaningful to everyone. We started with the elderly population, we are going to move into couples and family planning, and eventually newborn screening. We are going to bring genetic testing to everyone and in the process, transform healthcare to improve the health of the population, one family at a time.
I want Artemis DNA to be the Amazon of genetic testing. Amazon changed how people shop, Artemis DNA will change how people understand their health.”
Ms. Thai earned her B.S. in Management and Operations Management from California State University, Long Beach and is enrolled in the Advanced Management Program (Leadership) at Columbia Business School, alumni status (February 2022).
Ann Sabahat, CPA MST
Chief Financial Officer
Ms. Ann Sabahat is a highly versatile, decisive corporate finance executive offering over 25 years of hands-on experience in financial management, with contributions leading to improved financial performance, heightened productivity, and enhanced internal control.
Ms. Sabahat holds a Masters in Taxation, as well as a CPA license. Her areas of expertise includes: strategic planning, financial and management reporting, mergers and acquisitions, revenue cycle management & automation, debt negotiations, IPO readiness, Sarbanes-Oxley (SOX) and SEC reporting, GAAP & SAP, and regulatory accounting, policies & procedures.
Prior to Artemis DNA, Ms. Sabahat served as Chief Financial Officer for Karat Packaging Inc, a specialty distributor & manufacturer of single-use disposable food service products company that she helped take public in 2021 (Symbol: KRT) and also as a Corporate Financial Controller for Western Dental and Orthodontics, a $1 billion in revenue multi-state general & specialty dental service provider network.
Chief Legal Officer & Corporate Secretary
Ms. Margaret Kivinski is a highly experienced general corporate counsel with intellectual property expertise. She has more than twenty years’ legal experience, primarily in-house with high-growth medical technology companies. She has a strong technical background and demonstrated strengths in patent portfolio growth and management, licensing, litigation management, business contracts and company administration for medical device and pharmaceutical companies.
Ms. Kivinski received her B.S. in Chemical Engineering from UCLA and is a registered professional engineer in California. She obtained her J.D. from Western State University College of Law, is admitted to state and federal courts in California, the Ninth and Federal Circuit courts of appeal, and is a registered patent attorney with the USPTO.
J. Dianne Keen-Kim, Ph.D, FACMG, HCLD(ABB)
CLIA Lab Director
Dr. J. Dianne Keen-Kim joined Artemis DNA to direct the CLIA Laboratory in January 2021. After earning her B.S. from Carnegie Mellon and Ph.D. from MIT in Clinical Molecular Genetics and Clinical Cytogenetics. Dr. Keen-Kim completed fellowships at UCLA and is certified by the American Board of Medical Genetics and Genomics (ABMGG) in both molecular genetics and cytogenetics.
Dr. Keen-Kim maintains clinical director licenses in CA and NY, and has expertise in building, validating, and process-improving clinical laboratory tests, including automating manual assays. Prior to Artemis DNA, Dr. Keen-Kim served in a variety of clinical, quality, regulatory and operational laboratory leadership roles at Natera, Color Genomics, Genoptix Medical Laboratory (a Novartis company), UCLA, and Quest Diagnostics.
Reza S. Davoodi, MSc. Ph.D, HCLD(ABB)
Associate Lab Director
Dr. Reza Davoodi has several years’ leadership experience in a CLIA diagnostics laboratory and many years’ experience as a principal investigator in academia conducting translational research. Dr. Davoodi has 24 peer-reviewed published papers. He was awarded several fellowships and grants, including an NIH grant on his research investigating the Jak-Stat signaling pathway to prevent and reverse type-1 diabetes in NOD mice.
Dr. Davoodi is licensed in the State of Florida (Director License in Molecular Pathology), the New York state (COQ) and in California state (CGMBS) and holds HCLD board certification (ABB) in molecular diagnostics.
Cynthe Sims, Ph.D, HCLD (ABB)
NYS Lab Director & Technical Supervisor
Dr. Cynthe Sims has a deep understanding and expertise in clinical laboratory solutions, clinical genomics, precision medicine, molecular diagnostics and next generation sequencing. Dr. Sims has assisted small laboratories, Fortune 500 companies, international government agencies and large healthcare systems plan and launch their precision medicine initiatives.
Dr. Sims is licensed in the State of Florida (Director License in Molecular Pathology), New York state (COQ) and in California State (CGMBS) and holds HCLD board certification (ABB) in molecular diagnostics.
Luisa Florez, MD
CLIA Lab Director
Dr. Florez is a board-certified pathologist and has served a laboratory director since 2013 for several laboratories of moderate and high complexity in the areas of Houston, Dallas, and Austin. She is a graduate of Tulane University with a degree in Anatomic Pathology.
Prior to coming to the United States, she had obtained a degree in Anatomic and Clinical Pathology from Universidad del Valle in Cali, Colombia. Dr. Florez is a member of the American Society Clinical Pathology (ASCP), the College of American Pathologists (CAP) and the Texas Medical Association (TMA) among others.